Zoetis Inc.
ZTSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Zoetis Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions. At a $33.48B market cap, Zoetis Inc. ranks as a large-cap company within healthcare. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.
Market Cap
$33.48B
Beta
0.74
P/E (TTM)
13.33
P/E (Fwd)
12.38
EPS (TTM)
$6.08
EPS (Fwd)
$6.54
ROE
64.9%
ROA
15.3%
Cash
$1.68B
Total Debt
$9.26B
Free CF
$2.02B
52W Change
-45.1%
Annual Financials
Cash vs Debt
Where ZTS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ZTS finished 6.73% below its 150-day moving average ($85.33) and 16.15% below its 200-day moving average ($94.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZTS overbought or oversold?
At the October 20, 2026 close, ZTS's RSI(14) was 81.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ZTS has $1.68B in cash with $9.26B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $2.02B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 64.9%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 15.3% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $8.08B to $9.47B.
Zoetis Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Zoetis Inc.'s trajectory.